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Objective: Cervical cancer is the third most common type of cancer in women worldwide and radiotherapy remains
its predominant therapeutic treatment. Artesunate (ART), a derivative of artemisinin, has shown radiosensitization effect
in previous studies. However, such effects of ART have not yet been revealed for cervical cancer cells.
Methods: The effect of ART on radiosensitivity of human cervical cancer cell lines HeLa and SiHa was assessed using
the clonogenic assay. Cell cycle progression and apoptosis alterations were analyzed by flow cytometry. For in vivo
study, HeLa or SiHa cells were inoculated into nude mice to establish tumors. Tissues from xenografts were obtained to
detect the changes of microvessel density, apoptosis and cell cycle distribution. Microarray was used to analyze
differentially expressed genes.
Results: ART increased the radiosensitivity of HeLa cells (SER = 1.43, P < 0.001) but not of SiHa cells. Apoptosis and the
G2-M phase transition induced by X-ray irradiation (IR) were enhanced by ART via increased Cyclin B1 expression in
HeLa cells. Tumor growth of xenografts from HeLa but not SiHa cells was significantly inhibited by irradiation combined
with ART (tumor volume reduction of 72.34% in IR + ART group vs. 41.22% in IR group in HeLa cells and 48.79% in
IR + ART group vs. 44.03% in IR alone group in SiHa cells). Compared with the irradiated group, cell apoptosis was
increased and the G2/M cell cycle arrest was enhanced in the group receiving irradiation combined with ART.
Furthermore, compared with radiation alone, X-ray irradiation plus ART affected the expression of 203 genes that
function in multiple pathways including RNA transport, the spliceosome, RNA degradation and p53 signaling.
Conclusion: ART potently abrogates the G2 checkpoint control in HeLa cells. ART can induce radiosensitivity of HeLa
cells in vitro and in vivo.
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Cervical cancer used to be the number 1 killer of female
human beings who suffered from cancer, with the devel-
opment of general survey technique, the morbidity of
cervical cancer decreased recently. However, cervical
cancer remains the third most common type of cancer* Correspondence: jpcao@suda.edu.cn
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developed areas, and radiotherapy is a common treatment
for this gynecological malignancy [1]. Radiotherapy for
cancer of the cervix can be external or/and internal, which
treats cervical cancer by using high-energy rays and des-
troy the cancer cells while doing as little harm as possible
to normal cells. However, radioresistance remains one of
the major reasons for clinical failure of radiotherapy [2].
Thus, to improve the efficacy of radiotherapy for cervical
cancer, the combination of radiation with additional radio-
sensitizing agents is needed.
Artemisinin, a chemical compound derived from the
sweet wormwood plant (Artemisia annua), has been well. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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humans for years. Various derivatives of artemisinin, in-
cluding artesunate, artemether, dihydroartemisinin (DHA)
and arteether have been identified [3,4]. Artesunate (ART)
is a semi-synthetic derivative of artemisinin and a more
effective antimalarial agent [5]. ART reveals remarkable
activity against otherwise multidrug-resistant Plasmodium
falciparum and P. vivax malaria. ART has also showed
anticancer activity against a variety of cancer cells,
especially in leukemia and colon cancer cell lines. The
anticancer activity of ART is associated with multiple
mechanisms, including reactive oxygen species (ROS),
oxidative DNA damage, sustained DNA double-strand
breaks and apoptosis [6-8].
Artemisinin and its derivative dihydroartemisinin have
shown radiosensitizing effect in cervical cancer cells [9,10].
Recently, the ART has been implicated as an effective
radiosensitiser in glioblastoma cells by decreasing survivin
expression [11] and in lung cancer cells via increasing NO
production [12]. However, whether such an effect of ART
exists in cervical cancer cells remains elusive. This study
aims to investigate the radiosensitizing effects of ART and
underlying mechanisms in vitro and in vivo. Our results
show that artesunate selective radiosensitization of human
cervical cancer HeLa cells through abrogation of radiation-
induced G2 block and cell apoptosis.Materials and methods
Reagents and cell culture
ART was purchased from Sigma Chemical Co. (Sigma
Chemical Co: St. Louis, MO) and was dissolved in dimeth-
ylsulfoxide (DMSO, Solon, OH) to 10 mmol/L as stock so-
lution (−20°C stocked), and diluted by DMEM to final
concentration. For in vivo studies, ART was diluted with
sterile PBS at 5 mg/ml before each administration.
The human cervical cancer cell lines HeLa and SiHa
were kind gifts from Prof. Saijun Fan, Georgetown Univer-
sity. These cells were maintained in DMEM supplemented
with 10% FBS and antibiotics (100 units/ml penicillin G,
100 units/ml streptomycin sulfate; Gibco, Grand Island,
NY). Cells were grown in a 37°C incubator with 5% CO2.Cytotoxicity assay
Cells (2 × 103) were seeded into 96-well plates in 100 μl
of DMEM medium and were incubated for 24 h, and
then the cells were treated with indicated concentra-
tions of ART followed by incubated with 200 μg/ml MTT
(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium
bromide, Sigma) for 4 h. The reaction product was dis-
solved in DMSO. Absorbance was measured at back-
ground wavelength of 570 nm, reference wavelength of
630 nm using a microplate reader. Three independent
experiments were done in triplicate.Clonogenic assay
Clonogenic assay was performed as described previously
[10]. Cells were seeded into six-well plates at 500–2,000
cells/well depending on the dose of radiation. Twenty-
four hours after seeding, cells were treated with ART or
DMSO for 24 h. Cells were exposed to various doses (0, 2,
4, 6 and 8 Gy) of X-rays irradiation from linear accelera-
tors (Varian, USA) at a dose rate of 2 Gy/min; a 1.5-cm
bolus was used as a compensator. After radiation, drug-
containing media was immediately replaced by fresh
DMEM. The cells were then grown from 7–12 days to
allow for colony formation and subsequently fixed and
stained using crystal violet. Colonies consisting of 50 or
more cells were counted as clones.
Measurement of apoptosis
Cells were treated with ART for 24 h prior to treatment
with 2 or 6 Gy irradiation. Apoptosis was measured using
propidium iodide (PI)/Annexin-V double staining follow-
ing manufacturer’s instructions (Keygen Biotech, Nanjing,
China). Cells were harvested 24 h after treatment with
ART; apoptotic fractions were measured using flow cy-
tometry (Beckman, USA). The Annexin-V+/PI- cells are
early in the apoptotic process, the Annexin-V+/PI +
cells indicating late apoptosis. The percentage of both
kinds of cells was counted. The Annexin-V-/PI + cells
are considered to be necrotic cells.
For tissue samples, 5 μm xenograft sections were depar-
affinized in xylene and hydrated in decreasing concen-
trations of ethanol, and the terminal deoxynucleotidyl
transferase dUTP nick-end labeling (TUNEL) assay was
performed following manufacturer’s instructions (Keygen
Biotech, Nanjing, China). Ten random fields from 4 slides
per group were examined. TUNEL-positive brown nuclei
within tissues were counted. Data were expressed as the
percentage of apoptotic cells per field.
Cell cycle progression analysis
Cells were treated with ART for 24 h. Cells were then
changed with fresh medium and irradiated at the indicated
doses. 24 h after irradiation, both floating and attached
cells were harvested and analyzed using the procedures
described previously (10). For flow cytometry, 10,000 cells
per sample were collected (Beckman, USA).
For cell cycle analyses of tissue samples, tissue speci-
mens were taken from nude mice and mixed with 200 μl
0.25% trypsin and EDTA (1:1), stirred 1 min at room
temperature and then filtered with a 70 μm nylon net.
Tumor cells were collected and pooled with the cells
floating in the medium. Cell suspensions were centri-
fuged 5 min at 1,500 rpm, room temperature, then
washed and fixed with ethanol at 4°C overnight. All sam-
ples were then washed with PBS and resuspended in PI
(50 μg/mL) and RNase A (20 μg/mL) in PBS for 30 min
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cytometry (Beckman, USA).Western blot
Cells were treated for 24 h with ART. Cells were then
changed with fresh medium and irradiated at the indicated
doses. The cells were then washed twice with ice-cold PBS
and directly lysed in 200 μl of cell lysis buffer. Tumors
from nude mice were resected, homogenized and lysed.
Western blot was performed as described previously [13].
Primary antibodies against Wee1, Cyclin B1, P53 and
Cdc2 were all obtained from Santa Cruz Biotechnology
(Santa Cruz, CA) and used at a 1:1,000 -1:2,000 dilution.
β-Actin was used as the loading control and detected
using a mouse monoclonal anti-β-actin antibody (Santa
Cruz Biotechnology).Xenograft studies of nude mice
Four-week-old male outbred BALB/c mice were purchased
from Shanghai SLAC Laboratory Animal Co., Ltd. (Shang-
hai, China), and kept under specific pathogen-free condi-
tions. HeLa or SiHa cells (2 × 106) were suspended in
100 μl PBS and then inoculated subcutaneously into each
posterior flank region of BALB/c nude mice. When the
average volume of tumor achieved 5 mm× 5 mm× 5 mm,
mice were randomized into four groups as follows (5 ani-
mals per group): 1) Control group (no radiation, injection
of 200 μl sterile PBS once a day for 7 days), 2) ART alone
group (no radiation, injection of ART once a day for 7 days
at 100 mg/kg/day with a total volume of 200 μl), 3) Radi-
ation (IR) alone group (injection of 200 μl sterile PBS for
7 days and radiated at a dose of 10 Gy at the 7th day one
hour after the last PBS was injected, or 4) IR plus ART
treatment group (injection of 200 μl ART once a day for
7 days at 100 mg/kg/day and radiated at a dose of 10 Gy
on the 7 th day after ART treatment). Both PBS and ART
were intraperitoneal injected.
Tumor diameters were measured at regular intervals
with digital calipers, and the tumor volume in mm3 was
calculated using the formula: volume = (width)2 × length/
2. A tumor growth curve was constructed and data are pre-
sented as means ± SEM. Animals were sacrificed 21 days
after the first inoculation. All the animal study were ap-
proved by the Animal Experimentation Ethics Committee
of Soochow University.Immunohistochemistry (IHC)
Immunohistochemistry of CD 31 was performed as de-
scribed previously [13]. Fetal lung tissue was used as a
positive control, and omission of primary antibody was
performed as a negative control.Microarray analysis of gene expression
Total RNA was extracted from cells or tissues with
Trizol reagent (Invitrogen, Carlsbad, CA). Microarray-
based mRNA expression profiling was performed using
the Roche-NimbleGen (135 K array) Array (Roche, WI).
The microarrays contained approximately 45,033 assay
probes corresponding to all of the annotated human
mRNA sequences (NCBI HG18, Build 36). Total RNA
labeling and hybridization were performed using stand-
ard conditions according to manufacturer instructions.
Genes with an absolute fold change of 5 or greater were
subsequently subjected to pathway analysis using In-
genuity Pathway Analysis (Redwood City, CA).
Statistical analysis
Data were expressed as the mean ± standard error of the
mean (SEM) of at least three independent experiments.
Standard error bars are included for all data points. The
data were then analyzed using Student’s t-test when only
two groups were present, or assessed by one-way ana-
lysis of variance (ANOVA) when more than two groups
were compared. The interaction between ART and radi-
ation was tested using two-way ANOVA. The sensitizer
enhancement ratios (SER) were measured using Sigma-
plot software according to the multi-target single hit
model. Differences were considered statistically signifi-
cant when P < 0.05.
Results
ART induces cytotoxicity in human cervical cancer cells
To evaluate the anticancer effect of ART on cultured
human cervical cancer cells, HeLa and SiHa cells were
treated with different concentrations of ART. The OD
value of cells treated without ART were regarded as con-
trol (100%) and then the cell groups treated with differ-
ent concentration of ART were versus with control. The
MTT assay revealed that the inhibitory effects elicited by
ART were dependent on its concentration (Figure 1A
and B). The fifty percent inhibition concentration (IC50)
of ART against HeLa and SiHa cells was 5.47 μmol/L
and 6.34 μmol/L, respectively. To evaluate the sensitiz-
ing ability of ART on cervical cancer cells to irradiation,
moderately toxic doses that reduced cell viability to ap-
proximately 90% were used. ART induced approximately
10% inhibition of HeLa cell viability with the concentra-
tion of 2.0 μmol/L, which was comparable to the effect
of 2.5 μmol/L ART on SiHa cells. These concentrations
were chosen for subsequent experiments.
ART increases the radiosensitivity in HeLa but not SiHa
cells
To investigate the influence of ART on the radiosensitiv-
ity of HeLa and SiHa cells, we performed an in vitro clo-
nogenic cell survival assay. HeLa cells pretreated with
Figure 1 Cytotoxicity of ART on HeLa and SiHa cells. The ART-induced cytotoxicity in (A) HeLa and (B) SiHa cells. HeLa and SiHa cells were
exposed to indicated concentrations of ART for 24 h. Cell survival was assessed using an MTT assay. The data are shown as the mean values ± the
standard error of the mean (SEM) for three independent experiments.
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cantly lower clonogenic survival fractions than cells
treated with radiation alone. The sensitizer enhance-
ment ratio (SER) was 1.43 for cells treated with radi-
ation plus ART, compared to cells treated with radiation
alone (Figure 2A). SiHa cells treated with radiation plus
2.5 μmol/L ART exhibited a SER of 1.03 (Figure 2B).
The data were further analyzed using two-way ANOVA
to test the interaction effect between ART and radiation.
Our results indicated that interaction between ART and
radiation was statistically significant (P < 0.001) forFigure 2 The ART-induced radiosensitivity in HeLa (A) and SiHa (B) ce
p53-overexpression HeLa and SiHa cells. Western blot of p53 and internal c
(D) cells. Clonogenic cell survival curves were generated for HeLa and SiHa
24 h and then were exposed to 2, 4, 6 or 8 Gy IR. The survival data were n
shown as mean ± SEM for three independent experiments. The SER was ca
ART prior to X-ray irradiation according to the multi-target single hit mode
experiments. *P < 0.05; **P < 0.01, compared with irradiated cells.HeLa cells, suggesting that ART treatment sensitized cells
to X-ray irradiation. However, in SiHa cells, the interaction
effect between ART and radiation was not statistically
significant (P > 0.05). Taken together, these results demon-
strated that treatment with ART could increase the radio-
sensitivity of human HeLa cells but not of SiHa cells.
We further investigated whether the difference be-
tween HeLa and SiHa cells in the ART-induced radio-
sensitizing effect is due to p53 status and expression
level. HeLa cells with mutant p53 were transfected with
a p53-overexpression vector (pcDNA3.1-p53). As shownlls. (C) and (D) The ART-induced radiosensitivity in wild-type
ontrol in pcDNA3.1- or pcDNA3.1-p53-transfected HeLa (C) and SiHa
cells that were treated with the indicated concentrations of ART for
ormalized to those of the unirradiated control group. The data are
lculated for HeLa or SiHa cells that were treated with 2.0 or 2.5 μmol/L
l. Values shown are the mean ± SEM for three independent
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tially reduce the radiosensitivity caused by ART (SER =
1.25) in HeLa cells, indicating that p53 status is likely to
be one of the reasons for the selective radiosensitizing
effect of ART. However, forced overexpression of p53
in SiHa cells significantly reduced the radiosensitizing
effect of ART (SER = 0.91, Figure 2D), indicating differ-
ent roles of p53 in the two types of cell lines.
ART induces apoptosis and necrosis in Hela cells
We next investigated whether reduced clonogenic survival
upon combined treatment with ART and X-ray irradiation
was associated with increased apoptosis and necrosis. As
shown in Figure 3A and B, 6Gy X-ray irradiation induced
apoptosis (Annexin-V+/PI- plus Annexin-V+/PI + cells)
and necrosis (Annexin-V-/PI + cells) in both HeLa and
SiHa cell lines, and 2Gy X-ray irradiation only induced
apoptosis but not necrosis in the two cell lines. This is
mainly because necrosis arises when exposed to high dos-
age. ART treatment further enhanced the apoptosis re-
sponse of HeLa cells to 2 or 6 Gy of irradiation (IR + ART
22.71% vs. IR 12.26% at 2 Gy, P < 0.05; IR + ART 59.92%
vs. IR 40.08% at 6 Gy, P < 0.05, Figure 3A). However, there
is no difference of the apoptosis response between radi-
ation plus ART and radiation alone group in SiHa cells
(IR + ART 14.35% vs. IR 12.276% at 2 Gy, P > 0.05; IR +
ART 33.67% vs. IR 32.25% at 6 Gy, P > 0.05). The percent-
age of necrotic cells was similar between ART-treated and
control cells in both cell lines (Figure 3A and B). Taken
together, these results demonstrate that ART augments
apoptotic cell death of HeLa cells in response to irradiation.
ART combined with X-ray irradiation modulates cell cycle
progression
DNA damage by radiation activates checkpoint pathways
that inhibit the progression of cells through G1 and G2
phases and delay progression through S phase. These
checkpoints provide cells with enough time to repair
damaged DNA prior to resuming cell cycle progression
[14,15]. To determine whether the observed ART-induced
radiosensitization was associated with changes in cell cycle
progression, HeLa and SiHa cells were cultured in DMEM
without serum for 24 h prior to the addition of ART, alone
or combined with 2 or 6 Gy X-ray irradiation. As shown
in Figures 4A and B, radiation induced a G2 arrest in the
p53-mutant HeLa cells and a G1 arrest in p53 wild-type
SiHa cells. Compared with irradiated cells, cells treatment
with ART plus X-ray irradiation showed decreased the
population of G2/M arrest in HeLa (but not SiHa) cells
(a reduction of 20.77% at 2 Gy and 36.24% at 6 Gy, P <
0.05). This result clearly indicates that ART abrogates the
G2 checkpoint but elicits no effect on the G1 checkpoint.
As Wee1, Cdc2 and Cyclin B1 play critical roles in the
control of the G2/M transition of the cell cycleprogression [16-18]. We then investigated whether ART
pretreatment modulated the expression of Wee1, Cyclin
B1 or Cdc2 after X-ray irradiation of HeLa and SiHa
cells. As shown in Figure 4C, 6 Gy X-ray irradiation in-
duced the expression of Wee1. The addition of ART
prior to irradiation resulted in decreased Wee1 and in-
creased Cyclin B1 expression in HeLa cells (Figure 4C,
left panel). In contrast, relative expression of Cdc2,
Wee1 and Cyclin B1 remained unaltered in SiHa cells.
These results indicated that combined treatment of ART
and radiation reduced Wee1 and increased Cyclin B1
expression, abrogating the G2/M arrest induced by
radiation in HeLa cells.
Irradiation combined with ART inhibits the growth of
HeLa xenografts
As shown in Figure 5A and 6B, mice treated with ART
alone yielded similar results as the control group. Com-
pared with the control group, the tumor volume of mice
treated with radiation alone was reduced by 41.22%.
Comparatively, HeLa xenografts that received com-
bined treatment of 10 Gy radiation and ART exhib-
ited much smaller tumors compared with mice that
received radiation alone (volume reduction of 72.34%
in IP + ART group), which suggests that ART can
enhance radiosensitivity of HeLa xenografts. Consist-
ent with in vitro studies, the radiosensitivity of SiHa
xenografts was not significantly changed (volume
reduction of 44.03% in IR alone group vs 48.79% in
IR + ART group; P > 0.05).
ART reduces microvessel density, promotes apoptosis and
inhibits G2-M phase arrest in vivo
To explore the mechanism for the tumor growth differ-
ence, the expression of CD31 which is an endothelial cell
surface molecule that can be used to visualize micro-
vessel density was detected by IHC. The results showed
that xenografts from the control group or from ART
treatment alone shared similar expression levels of
CD31 (Figure 5C and D). Xenografts from the irradi-
ation plus ART treatment group displayed significantly
less positive staining for CD31 in HeLa xenografts
(9.75% in IR + ART group vs. 24.25% in IR group,
P < 0.05, Figure 5C) but not in the SiHa counterparts
(Figure 5D). These results indicated that irradiation
combined with ART influences the formation of
microvessels and consequent tumor growth in HeLa
xenografts.
We then measured cell apoptosis using the TUNEL
assay to further investigate the apoptotic status in xeno-
grafts,. As shown in Figures 6A and B, irradiation plus
ART resulted in significantly higher apoptotic cell death
in the xenografts compared with IR alone group (50.30%
in IR + ART group vs. 30.20% in IR group, P < 0.05,
Figure 3 Induction of apoptosis by ART and radiation in HeLa and SiHa cells. Cells were treated with ART for 24 h prior to treatment with 2
or 6 Gy irradiation. Apoptosis and necrosis were measured using propidium iodide (PI)/annexin-V double staining in (A) Hela and (B) SiHa cells.
The data are shown as mean ± SEM for three independent experiments. Statistical analysis between the groups was determined by ANOVA; *P < 0.05.
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bined with ART enhanced radiation-induced apoptosis
in HeLa xenografts.To determine whether irradiation plus ART influenced
cell cycle progression in xenografts, flow cytometry was
performed. The effect of combined radiation and ART
Figure 4 The effect of ART and radiation on HeLa (A) and SiHa (B) cell cycle progression. Cells were treated with or without 2.0 μmol/L
(HeLa) or 2.5 μmol/L ART (SiHa) for 24 h prior to exposure to 6 Gy irradiation (IR). After 24 h, both attached and floating cells were harvested for
cell cycle analysis. The expression of Wee1, Cyclin B1 and Cdc2 in HeLa (C) and SiHa (D) cells. HeLa and SiHa cells were treated with or without
ART for 24 h prior to exposure to 6 Gy of X-ray irradiation (IR). The expression levels of Wee1, Cyclin B1, Cdc2 and the internal control β-Actin
were evaluated by Western blot.
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Treatment with ART alone leads to no observed changes
while comparing with the control group. However,compared with the radiation group, the percentage of
tumor cells in G1 phase was significantly increased by
9.52% (P < 0.05, Figure 6C) while the percentage of G2
Figure 5 The effect of ART on the growth and CD31 expression of xenografts. Each group of mice was composed of five male nude mice.
HeLa (A) or SiHa cells (B) were inoculated under the skin of nude mice. Tumor size was measured at 2 day intervals. *P < 0.05, compared with IR
alone group. Data are presented as means ± SEM. Representative IHC showing CD31-stained microvessels in the xenografts from HeLa (C) and
SiHa cells (D). Scale bar represents 50 μm (magnification, × 400).
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Figure 6C) in the radiation combined with ART group.
It is likely that ART decreases G2 phase arrest of
tumor cells after irradiation. We next examined the
expression of Cyclin B1 and Cdc2 in the HeLa xeno-
grafts. As shown in Figure 6D, increased Cyclin B1
protein levels from xenografts were consistent with
those in the previous in vitro study. However, the ex-
pression of Cdc2 was not changed in these xenografts,
suggesting that the cell cycle changes may be triggered
by Cyclin B1.
ART increases radiosensitivity of HeLa cells via complex
mechanisms
To further analyze the underlying mechanisms respon-
sible for ART-mediated radiosensitivity, we profiled gene
expression between HeLa cells after either 6 Gy X-ray ir-
radiation or the combination of 2.0 μmol/L ART prior
to 6 Gy X-ray irradiation. Twenty-four hours after the
treatments, a total of 203 genes (91 upregulated and 112downregulated genes) were identified with differential
expression of 5-fold or more between the two groups of
cells (Figure 7A and Table 1). Consistent with previous
findings [19,20], the administration of ART remarkably
inhibited the expression of genes associated with hemoglo-
bin and immunoglobulin. As expected, ART seems to
modulate the radiosensitivity of HeLa cells via complex
mechanisms. Pathway analysis revealed that ART treat-
ment affected multiple pathways including RNA trans-
port, the spliceosome, RNA degradation, p53 signaling
and MAPK (Figure 7B and C).
Discussion
The anti-malarial ART has been reported to act against
a variety of cancer cells including leukemia, lung and
colon cancer cell lines [21-23]. Previously, we have re-
ported that artemisinin and its analog dihydroartemisi-
nin are effective radiosensitisers for cervical cancer cells
[9,10]. In this study, we found that another artemisinin
derivative, ART, increased the radiosensitivity and
Figure 6 The effect of ART on the apoptosis and cell cycle progression of HeLa xenografts. (A) Representative TUNEL assays showing
apoptosis in HeLa xenografts(magnification, × 400). (B) Percentage of TUNEL-positive cells per field are expressed as means ± SEM. *P < 0.05,
compared with radiation alone group. (C) The cell cycle distributions of the xenografts were analyzed. Values shown are the mean ± SEM.
(D) Western blot analysis of Cyclin B1, Cdc2 and Wee1 in the HeLa xenografts.
Figure 7 Predicted significant pathways involved. (A) Heat map of gene expression between HeLa cells after 6 Gy X-ray irradiation or
2.0 μmol/L ART prior to 6 Gy X-ray irradiation. (B) Predicted significant pathways for upregulated genes. (C) Predicted significant pathways for
downregulated genes.
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Table 1 Microarray gene expression changes relative to irradiated HeLa cells (X-ray irradiation plus ART vs. X-ray
irradiation alone)
Gene name Fold change upregulated Chromosome Description
IMAA 14.44 chr16 SLC7A5 pseudogene
HSUP1 10.05 chr20 Similar to RPE-spondin
FLJ11021 9.10 chr12 Similar to splicing factor, arginine/serine-rich 4
KIAA1904 8.98 chr22 KIAA1904 protein
ZRF1 8.95 chr7 Zuotin related factor 1
SDCCAG10 8.61 chr5 Serologically defined colon cancer antigen 10
LOC442573 8.47 chr7 Similar to postmeiotic segregation increased 2-like 2
EIF3S10 8.42 chr10 Eukaryotic translation initiation factor 3, subunit 10 theta
KTN1 8.34 chr14 Kinectin 1 (kinesin receptor)
LOC642617 8.23 chr2 Hypothetical protein LOC642617
LOC340089 7.98 chr5 Similar to nuclear pore membrane protein 121
GPR18 7.97 chr13 G protein-coupled receptor 18
LOC646074 7.93 chr22 Similar to nuclear pore membrane protein 121
NOL8 7.71 chr9 Nucleolar protein 8
AHNAK 7.26 chr11 AHNAK nucleoprotein (desmoyokin)
N/A 7.16 chr3 Homo sapiens cDNA clone MGC:99509 IMAGE:3939369
GOLGA4 7.10 chr3 Golgi autoantigen, golgin subfamily a, 4
LOC646316 6.95 chr4 Similar to Telomeric repeat binding factor 1
interacting protein 2)
CENPF 6.92 chr1 Centromere protein F, 350/400 ka (mitosin)
LOC643211 6.91 chr2 Hypothetical protein LOC643211
Gene name Fold change downregulated Chromosome Description
HBB 116.84356 chr11 Hemoglobin, beta
HBB 110.22069 chr11 Hemoglobin, beta
IGHG1 93.40286 chr14 Immunoglobulin heavy constant gamma 1 (G1m marker)
N/A 60.31211 chr2 Anti-rabies SOJA immunoglobulin kappa light chain mRNA
IGHG1 59.625664 chr14 Immunoglobulin heavy constant gamma 1 (G1m marker)
IGKC 56.961563 chr2 Immunoglobulin kappa constant
IGKC 50.49672 chr2 Immunoglobulin kappa constant
HBD 43.09641 chr11 Hemoglobin, delta
IGHG1 42.666557 chr14 Immunoglobulin heavy constant gamma 1 (G1m marker)
IGHG1 40.846592 chr14 Immunoglobulin heavy constant gamma 1 (G1m marker)
IGKC 37.99056 chr2 Immunoglobulin kappa constant
IGHA1 36.901497 chr14 Immunoglobulin heavy constant alpha 1
IGKC 34.52912 chr2 Immunoglobulin kappa constant
IGLV3-25 28.34214 chr22 Immunoglobulin lambda variable 3-25
PLUNC 25.71026 chr20 Palate, lung and nasal epithelium carcinoma associated
IGLV3-25 25.19829 chr22 Immunoglobulin lambda variable 3-25
LOC652848 24.885628 chr14 Similar to Ig heavy chain V-II region ARH-77 precursor
N/A 19.36516 chr2 Homo sapiens cDNA clone MGC:104455 IMAGE:30352955
N/A 19.346416 chr22 Homo sapiens cDNA clone MGC:71261 IMAGE:4576612
IGHG1 17.280687 chr14 Immunoglobulin heavy constant gamma 1 (G1m marker)
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not of the wild-type p53 SiHa cells, both in vitro and
in vivo. In HeLa cells, combined ART and radiation
treatment decreased Wee1 but increased Cyclin B1 ex-
pression levels, impairing the irradiation-induced G2/M
arrest. ART decreased the G2/M arrest induced by radi-
ation, which most likely resulted in more irradiation-
damaged cells entering mitosis. Moreover, the combined
treatment of ART and irradiation increased apoptosis in
cultured HeLa cells and HeLa xenografts. In the in vivo
study, ART was given at a concentration of 100 mg/kg/
day regularly for 7 days to achieve effective blood concen-
tration in the nude mouse. Further investigation within
other levels of ART should be tested.
ART has been reported to induce DNA damage re-
sponse and repair genes, oncogenes, tumor suppressor
genes and apoptosis-regulating genes [7]. DNA-damaging
agents often induce cell cycle arrest in G1 or G2/M phases
[24,25], which are facilitated by checkpoint mechanisms
that provide time for the repair of sub-lethal DNA damage
prior to the resumption of cell cycle progression [26].
Therefore, the abrogation of the G2 checkpoint, which
promotes premature mitotic entry and subsequent cell
death, has emerged as a potential therapeutic strategy
[17,27]. Cells in G2/M phase are particularly susceptible
to the effects of radiation. Because of this, agents that alter
cell cycle progression are often potent radiation modifiers
[28]. In eukaryotic cells, Wee1 phosphorylates Cdc2 on
Tyr-15 and inhibits its kinase activity, thereby preventing
entry into mitosis [29-32]. Therefore, suppression of
Wee1 can reduce Cdc2 Tyr-15 phosphorylation and
lead to the activation of Cdc2 kinase. Irradiation expos-
ure can induce a G2/M arrest in HeLa cells through
increased and decreased expression of Wee1 and Cyclin
B1, respectively. We found that this cell cycle arrest and
protein expression change was reversed by treatment with
ART. The expression of Cdc2 exhibited no significant
changes in either HeLa or SiHa cells that were treated
with a combination of ART and irradiation, suggesting
that ART might affect Cdc2 indirectly through Wee1.
Wee1 is part of an intricate network of kinases and phos-
phatases that regulate the G2 checkpoint [33]; the abroga-
tion of this checkpoint by Wee1 inhibition results in
mitotic catastrophe. ART treatment resulted in similar ab-
rogation of the radiation-induced G2 arrest in HeLa cells.
However, ART elicited no significant inhibition effect on
G1/S arrest, similarly to artemisinin [9,10].
In this study, we found that ART exhibits different
radiosensitizing effects between HeLa and SiHa cells.
ART is reported to act via p53-dependent and -independ-
ent pathways in cancer cells [22]. The tumor suppressor
and transcription factor p53 is a major regulator of cellular
defense against neoplastic transformation and cancer devel-
opment [34-37]. Defects in p53-dependent pathways arecorrelated with tumor resistance to radiation and chemo-
therapy [35]. The present study used paired p53-positive
and p53-negative cancer cells to confirm the hypothesis
that abrogation of the G2 checkpoint by targeting Cyclin
B1 and Wee1 kinases represents an effective therapeutic
approach against p53-null cancer cells. Wild-type p53
might protect the genome from accumulating DNA dam-
age and transmitting genetic mutations to subsequent
daughter cells [34-36]. However, forced expression of wild-
type p53 could partially change the radiosensitizing effect
of ART in HeLa cells, which suggests that p53 status is only
one of the reasons for the selective radiosensitization of
ART. Such a phenomenon is also observed for artemisinin
and dihydroartemisinin [9,10].
As expected, ART seems to modulate the radiosensi-
tivity of HeLa cells via complex mechanisms by affecting
multiple pathways including RNA transport, the spliceo-
some and RNA degradation. ART treatment also in-
creased the transcripts of EIF3 (eukaryotic translation
initiation factor 3), which induces apoptosis in multiple
cancer cells [38]. However, we did not detect expression
changes of Wee1 or Cyclin B1 in cells pretreated with
ART, indicating that their expression changes may occur
at the protein level.
In summary, ART enhances radiation-induced apop-
tosis and relieves the G2/M arrest in vitro and in vivo,
which shows its promise as an effective radiosensitiser in
cancer therapy. Clinical application of this anti-malarial
drug can be expanded to complement radiotherapy for
cancers.
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